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Abstract
Background: Female sex has been reported as an independent predictor of severe post-liver transplantation (LT)
chronic kidney disease. We performed a by sex post-hoc analysis of the SURF study, that investigated the
prevalence of renal impairment following LT, aimed at exploring possible differences between sexes in the
prevalence and course of post-LT renal damage.
Methods: All patients enrolled in the SURF study were considered evaluable for this sex-based analysis, whose
primary objective was to evaluate by sex the proportion of patients with estimated Glomerular Filtration Rate
(eGFR) < 60 ml/min/1.73m2 at inclusion and follow-up visit.
Results: Seven hundred thirty-eight patients were included in our analysis, 76% males. The proportion of patients with
eGFR < 60mL/min/1.73m2 was significantly higher in females at initial study visit (33.3 vs 22.8%; p = 0.005), but also
before, at time of transplantation (22.9 vs 14.7%; p = 0.0159), as analyzed retrospectively. At follow-up, such proportion
increased more in males than in females (33.9 vs 26.0%, p = 0.04). Mean eGFR values decreased over the study in both
sexes, with no significant differences. Statistically significant M/F differences in patient distribution by O’Riordan eGFR
levels were observed at time of transplant and study initial visit (p = 0.0005 and 0.0299 respectively), but not at follow-up.
Conclusions: Though the limitation of being performed post-hoc, this analysis suggests potential sex differences in the
prevalence of renal impairment before and after LT, encouraging further clinical research to explore such differences
more in depth.
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Background
Liver transplantation is the only available treatment option
for several life-threatening liver conditions, including end-
stage liver disease, acute fulminant hepatic failure, and
hepatocellular carcinoma. Thanks to advanced surgical
techniques and the progress achieved in perioperative man-
agement and immunosuppressive therapy, outcomes are
currently satisfactory in terms of both short-term graft and
patient survival. The overall 1-year survival rates after a
liver transplant (LT) are 85% [1]. However, long-term out-
comes of liver transplant recipients are not as satisfactory,
given the high complication rate of long-term immunosup-
pressive therapy, including infections, malignancies and
renal failure [2]. The overall 5- and 10-year survival rates
after LT drop to 68, and 50% respectively [1]. Renal insuffi-
ciency, together with older age and diabetes, has shown to
identify patients at highest risk of poor survival, and actually
renal failure becomes a major cause of death with longer
follow-up. A recent multicentre study has shown that the
inflection point for increasing frequency occurs at the sixth
postoperative year [1]. Furthermore, estimates suggest that
around 20% of patients with chronic liver failure develop
renal dysfunction [3], even before transplantation [4]. Ele-
vated pre-operative serum creatinine levels are associated
with increased risk of requirement for post-operative
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dialysis [5, 6], and those not receiving renal replacement
therapy may be at greater risk of early graft failure than
those receiving renal replacement therapy. A low thresh-
old for instituting renal replacement therapy may there-
fore be beneficial [4, 7, 8]. The Kidney Disease Outcomes
Quality Initiative (K/DOQI) guidelines recommend glom-
erular filtration rate (GFR) evaluation as the best global
index of renal function, and state that it should be esti-
mated based on formulas that consider the serum creatin-
ine level and at least some of the following variables: age,
sex, race and body surface [9]. An eGFR below 60mL/
min/1.73m2 is considered an index of renal damage [10,
11], and a recent systematic review of the methodology
used in studies reporting chronic kidney disease preva-
lence reports that actually an eGFR < 60mL/min/1.73m2
was used to define Chronic Kidney Disease (CKD) in 92%
of studies [12]. Data from the literature show that patients
undergone LT who have a GFR < 60mL/min/1.73m2 3
months following transplant are at high risk of developing
chronic kidney disease [11, 13].
The SURF (Italian Observational Study for Renal Insuffi-
ciency Evaluation in Liver Transplant Recipients) was con-
ducted from 2012 to 2014, with the aim of assessing the
prevalence of reduced estimated Glomerular Filtration Rate
(eGFR < 60ml/min/1.73m2) in subjects underwent to pri-
mary orthotopic liver transplantation from 6months to 5
years before entering the study. The SURF study showed an
eGFR decline over time, particularly rapid in progression
over the first year from transplant. This was hypothesized to
be the result of the nephrotoxicity of CNIs, which were the
most common therapeutic approach in the clinical practice.
Women represent a particular group of patients with
chronic liver disease, not only given to a different body
mass index, and different aetiologies of liver disease, and
accessibility to transplantation, but also due to hormonal
factors [14]. Nevertheless, sex is scarcely taken into ac-
count when indications, risk factors, and outcomes con-
cerning LT are evaluated. In particular, regarding renal
impairment, female sex has been reported as an inde-
pendent predictor of severe post-LT chronic kidney dis-
ease [15]. The MetaGem project – i.e. the by sex
analysis of the data form observational studies con-
ducted between 2002 and 2013 – was started by Novar-
tis Italy in 2013 [16]. These studies covered many
different clinical areas, including autoimmune diseases,
such as psoriasis and psoriatic arthritis, liver and kidney
transplants, hepatitis B, and central nervous system dis-
eases, including Parkinson and Alzheimer. Through
post-hoc analyses and meta-analyses, the MetaGeM pro-
ject is aimed at analysing and describing therapeutic ap-
proaches, clinical outcomes, and safety data by sex, to
explore possible differences which may be useful in ad-
dressing future clinical research or specifically tailoring
therapeutic approaches.
Within the overall MetaGeM project, we here report a
post-hoc analysis of the SURF study data performed by
sex, with the aim of exploring if there are differences be-
tween sexes in the prevalence and course of renal dam-
age in LT recipients.
Methods
SURF was an observational, multicentre, Italian, two
phases study, one cross-sectional followed by a longitu-
dinal phase. Male or female patients undergone first liver
transplant in the previous 5 months to 5 years were en-
rolled in 15 Italian centres, provided they were aged ≥18
years at the time of transplantation, and were without
combined multiple-organ transplant and not included in
any experimental clinical trial at inclusion visit.
The SURF included just two visits, an enrolment visit,
performed according to the routine clinical practice, when
the retrospective data from inclusion to 30 days before LT
were collected, and a follow-up visit approximately 12
months (± 3months) after the inclusion visit, again per-
formed as usual clinical practice. The type, dosage and
duration of immunosuppressive therapy, and of all other
medical treatments were according to clinical practice.
The primary endpoint of SURF study was the assessment
of the proportion of patients with eGFR < 60ml/min/1.73
m2 at inclusion and at the 12-month follow-up visit.
All patients enrolled in both the cross-sectional and lon-
gitudinal phases of the SURF study were considered evalu-
able for this sex-based analysis whose primary objective
was to evaluate the proportion of patients with eGFR< 60
ml/min/1.73m2 at inclusion and follow-up visit by sex.
The secondary objectives were the following, evaluated
on the longitudinal population and stratified by sex: (i) to
describe eGFR distribution at inclusion and follow-up visit;
(ii) to describe eGFR change (slope) from transplant to in-
clusion visit and from inclusion to follow-up visit (12-
month observation period); (iii) to describe patient distribu-
tion by eGFR, proteinuria and slope category at inclusion
and follow-up visit; (iv) to describe immunosuppressive
therapy administered at inclusion visit and (v) to describe
the therapeutic approach during the 12-month observation
period based on eGFR status (eGFR < 60ml/min/1.73m2
and eGFR ≥60ml/min/1.73m2 at the inclusion visit).
As primary objective, the eGFR was computed accord-
ing to the MDRD-4 formula [17, 18]: eGFR = 186 x (cre-
atinine) -1.154 x (age) -0.203 x (1.212 if black) x (0.742 if
female) where age is expressed in years and creatinine in
mg/dL. If creatinine was reported in μmol/L, it was con-
verted in mg/dL by means of conversion factor 0.0114,
as follows: mg/dL =0.0114 x μmol/L. The prevalence
was calculated as the ratio between patients with eGFR
lower than 60ml/min/1.73 m2 and the total number of
evaluable patients.
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As regards secondary objectives, eGFR distribution at in-
clusion visit was described using mean, standard deviation,
quartiles, minimum and maximum. Furthermore, eGFR
values were classified in 5 levels according to O’Riordan
[19]: level 1 (eGFR ≥90ml/min/1.73m2), level 2 (eGFR be-
tween 60 and 89ml/min/1.73m2), level 3 (eGFR between
30 and 59ml/min/1.73m2), level 4 (eGFR between 15 and
29ml/min/1.73m2) and level 5 (eGFR < 15ml/min/1.73
m2). Absolute and relative frequencies were provided.
The eGFR annual average change (slope) from trans-
plant to inclusion visit was calculated as follows: (eGFR
at time t2 – eGFR at time t1) / [(t2-t1)/365.25] where
t1 = date of creatinine assessment at transplant, and t2 =
date of creatinine assessment at inclusion visit. eGFR
change per patient was described using mean, standard
deviation, quartiles, minimum and maximum. eGFR
slope was described overall and by time from transplant.
The GFR level, its variation (slope) and proteinuria are
important elements that, if combined, could provide an
early picture of the renal function condition. From the
combination of eGFR, slope and proteinuria and accord-
ing to literature data, the Advisory Board of the SURF
study identified different categories of renal dysfunction,
as showed in Table 1 [1, 20–24]. The distribution of LT
patients’ according to these categories was provided too.
To describe the therapeutic approach according to eGFR
values during the 12-month observational period, the pro-
portion of patients who changed therapy during observation
period was described by eGFR classes (i.e. eGFR< 60ml/
min/1.73m2 vs eGFR ≥60ml/min/1.73m2) at inclusion visit.
Patients with missing data for one or more variables
were not excluded from the analyses, they simply were
not evaluated for that variable(s). Comparisons between
males and females were performed by Student t-test,
Wilcoxon-Mann-Whitney test, χ2 test and Fisher exact
test if appropriate. The accepted level of significance was
set to alpha = 0.05.
The analyses were performed using SAS v.9.2 and En-
terprise Guide v.4.3.
Results
Out of 1029 enrolled patients in the SURF study, 1002
(97.4%) met eligibility criteria for the cross-sectional
phase; out of those patients, 753 entered in the longitu-
dinal phase, of whom 738 were evaluable and included
in the analysis. Out of these 738 patients, 561 (76.0%)
were males. Demographic and baseline characteristics,
and patients’ history of liver disease and liver transplant-
ation are summarized in Table 2. The mean ± SD age at
inclusion was 56.2 ± 8.7 in men vs 53.2 ± 12.2 years in
women (T-test p-value = 0.00291) and the mean ± SD
age at transplant was 53.8 ± 8.5 in men vs 50.8 ± 12.2
years in women (p-value (T-test) = 0.00283). The pro-
portion of HCV-positivity was significantly higher in
males (47.4% vs 28.8% in females; p-value (χ2
test) < .0001).
Eight patients had chronic liver rejection ongoing at
inclusion visit (4 males and 4 females), while one or
more acute liver rejections from transplant to inclusion
visit had been experienced by 129 patients (12.8%; 16.6%
of females and 11.7% of males; p-value (χ2 test) males vs
females = 0.04767).
Overall, 187 patients (25.3%) had an eGFR < 60mL/
min/1.73 m2 at the initial study visit, representing 22.8%
of the male population and 33.3% of females (p-value (χ2
test) males vs females = 0.0050), while at the follow-up
Table 1 Combination of eGFR, proteinuria and slope values defining the SURF study categories
Category eGFR Proteinuria Annual slopea
1 ≥ 90ml/min NO/NA Any
2 ≥ 90ml/min YES Any
60–89 ml/min NO/NA Decrease ≤4 ml/min or any increase
3 60–89 ml/min NO/NA Decrease > 4ml/min
60–89 ml/min YES Decrease ≤4 ml/min or any increase
30–59 ml/min NO/NA Decrease ≤4 ml/min or any increase
4 60–89 ml/min YES Decrease > 4ml/min
30–59 ml/min NO/NA Decrease > 4ml/min
30–59 ml/min YES Decrease ≤4 ml/min or any increase
5 30–59 ml/min YES Decrease > 4ml/min
< 30 ml/min NO/NA Decrease ≤4 ml/min or any increase
6 < 30 ml/min NO/NA Decrease > 4ml/min
< 30 ml/min YES Any
Categories were identified by the Advisory Board of the SURF study
NA Not available
aAnnual slope is intended as annual average variation of eGFR obtained over a period ≥5months
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visit the proportion increased overall to 27.9% (n = 206),
and the increase was greater in males (26.0%) than in fe-
males (33.9%) (p-value (χ2 test) males vs females =
0.04176). Retrospectively analysing eGFR values at the
time of transplantation, the overall percentage of pa-
tients below 60mL/min/1.73 m2 was lower (16.7%), and
already slightly significantly higher among females
(22.9%) than males (14.7%) (p-value (χ2 test) males vs fe-
males = 0.0159).
Mean (SD) eGFR values decreased from a mean value of
94.5 (37.3) ml/min/1.73m2 at transplant to 76.2 (25.5) at
inclusion visit and to 74.6 (25.4) at follow-up visit, with no
significant differences between males and females. Patient
distribution according to O’Riordan levels of eGFR at each
time point are summarized in Table 3. Statistically
significant male/female differences were observed at the
time of transplant and at the study initial visit (Fisher exact
test p-values 0.0005 and 0.0299 respectively), but not at
follow-up.
Annual average eGFR change (slope) from transplant
to inclusion visit was much higher in the subgroup of
patients undergone liver transplantation 6–12months
before SURF inclusion visit (Table 4), and almost double
in females compared to males. The annual average
change in eGFR, as assessed during each year from
transplant, was also higher during the first post-
transplant year (mean − 16.4 ml/min/1.73 m2) than in the
following years, with a greater decline in men (mean −
18.0) than in women (mean − 11.2) that did not achieve
statistical significance. The median difference between
Table 2 Demographic and baseline characteristics, and history of LT
Females Males Total
(n = 177) (n = 561) (n = 738)
Age (years) at LT, mean (SD) 50.8 (12.2) 53.8 (8.5) 53.1 (9.6)
Age (years) at inclusion visit, mean (SD) 53.2 (12.2) 56.2 (8.5) 55.5 (9.7)
BMI 6 months after LT, mean (SD) 24.0 (4.1) 25.0 (3.1) 24.8 (3.4)
BMI at inclusion visit, mean (SD) 25.2 (4.5) 26.1 (3.3) 25.8 (3.7)
BMI at follow-up visit, mean (SD) 25.7 (4.9) 26.4 (3.5) 26.2 (3.9)
Time (months) from liver transplant to inclusion visit, mean (SD) 29.1 (16.1) 28.9 (16.3) 29.0 (16.2)
Time (months) from liver transplant to inclusion visit by class
[5 months; 1 year) 31 (17.5%) 97 (17.3%) 128 (17.3%)
[1 year; 2 years) 46 (26.0%) 158 (28.2%) 204 (27.6%)
[2 years; 3 years) 38 (21.5%) 105 (18.7%) 143 (19.4%)
[3 years; 4 years) 31 (17.5%) 108 (19.3%) 139 (18.8%)
[4 years; 5.5 years] 31 (17.5%) 93 (16.6%) 124 (16.8%)
MELD score at transplant, mean (SD) 18.2 (8.4) 17.47 (7.1) 17.7 (7.4)
MELD score at transplant by class, N (%)
Low MELD (<=14) 54 (36.2%) 196 (41.4%) 250 (40.2%)
Intermediate MELD (15–24) 65 (43.6%) 208 (44.0%) 273 (43.9%)
High MELD (> = 25) 30 (20.1%) 69 (14.6%) 99 (15.9%)
NA 13 38 51
Not Recorded 15 50 65
Main conditions leading to LT (> 10%), N (%)
Hepatocellular carcinoma in cirrhotic liver + cirrhosis, HCV+ 27 (15.3%) 143 (25.5%) 170 (23.0%)
Hepatocellular carcinoma in cirrhotic liver + cirrhosis, HCV- 15 (8.5%) 110 (19.6%) 125 (17.0%)
Cirrhosis, HCV+ 23 (13.0%) 120 (21.4%) 143 (19.4%)
Cirrhosis, HCV- 70 (39.6%) 149 (26.6%) 219 (29.7%)
HCV+ and HBV+ patients having hepatocellular carcinoma in
hepatic liver or cirrhosis as disease leading to liver transplantation
HBV+ 34 (19.2%) 137 (24.4%) 171 (23.2%)
HCV+ 51 (28.8%) 266 (47.4%) 317 (43.0%)
LT liver transplantation, BMI body mass index, MELD Model for End-stage Liver Disease, HBV hepatitis B virus, HCV hepatitis C virus
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sexes was significant only at the fourth post-transplant
year, when females improved, and men slightly declined.
The median [25th percentile; 75th percentile] was + 1.4
ml/min/1.73 m2 [− 2.4;13.3] in females and − 1.8 [− 8.3;
6.1] in males, p-value (Wilcoxon-Mann-Whitney test) =
0.0024. Proteinuria was present in 20.9% of patients at
inclusion and in 23.1% at follow-up, with no between
sexes difference.
Coming to the eGFR, proteinuria and slope combined
categories, there was a little shift from the first two classes
to the higher ones from inclusion to follow-up visit, but
with no significant differences between sexes (see Fig. 1).
Immunosuppressive therapy, as registered at inclusion
visit, included CalciNeurin Inhibitors (CNI) in more
than 90% of patients (74% tacrolimus, 18% cyclosporine):
in 50.8% as monotherapy, and in 38.6% in combination
with mycophenolate or everolimus, the rest with other
medications. At least one change in immunotherapy in
terms of actives was reported in 46.9% of patients from
transplant to inclusion visit with no differences between
sexes (p-value (χ2 test) males vs females = 0.73182), and
in 16.3% from inclusion to follow-up visit, with no dif-
ferences between eGFR levels (p-value (χ2 test) eGFR <
60ml/min/1.73 m2vs eGFR ≥60ml/min/1.73 m2 =
0.19953) nor sexes (p-value (χ2 test) eGFR < 60 vs eGFR
≥60 in male population = 0.07929; p-value (χ2 test) eGFR
< 60 vs eGFR ≥60 in female population = 1.000).
Discussion
The SURF study, was conducted from 2012 to 2014,
with the aim of assessing the prevalence, in subjects
underwent to primary orthotopic liver transplantation,
of eGFR < 60 ml/min/1.73 m2, which is a recognized
index of renal damage and an indicator of poor post-
transplant prognosis. The results have been first ana-
lysed in the overall study population. Then, given the
growing interest in sex medicine and the recognised
need to be mindful of sex differences in designing clin-
ical protocols and treatment pathways to improve out-
comes in LT [16, 25–27], a post-hoc by-sex analysis of
the SURF patients participating in the longitudinal
follow-up phase was performed.
The first relevant result is that three quarter of the
transplanted patients in the participating centres were
males. This is not surprising, given that epidemiological
data report that men have higher rates of liver cancer
than women, and liver cancer is a common cause of LT.
It has been postulated that oestrogens play a protective
role in women with chronic liver disease: experimentally,
oestrogens have been shown to exert a strong suppres-
sive role on fibrosis in a rat model [28, 29], and in the
clinical setting, menopause has been associated with
higher degrees of fibrosis [30, 31]. Another issue, may be
the access to LT among women. It has been recently re-
ported that females comprised 35% of transplant recipi-
ents in 2013 [32], their number constantly declined
since 2002 [27]. Data suggest that this proportion of
women is also less likely to undergo LT once listed and
have a greater probability of dying or becoming too sick
to undergo liver transplantation compared to men [33].
Except from the size, male and female populations in
our study were rather homogeneous for demographic
and clinical baseline characteristics, however a signifi-
cantly higher proportion of HCV-positive subjects was
registered among males. Once again, this is consistent
with previous data indicating that hepatitis B and C are
more common in males [34–36]. A National Health and
Nutrition Examination Survey (NHANES) conducted be-
tween 2003 and 2010 found men to be significantly
more likely to be chronically infected with hepatitis C
virus than women [37]. Moreover, the progression of fi-
brosis in patients with chronic HCV is twice as rapid in
men versus women [38, 39], and this may further justify
the greater prevalence of men undergoing LT.
Following LT, eGFR values, according to the literature,
are highly variable and dependent from time elapsed from
transplant: in the TRY study [40], the percentage of patients
with eGFR < 60ml/min/1.73m2 ranged from 48% after 1
month to 58% after 5 years from transplant. According to
Table 3 Patient distribution according to O′ Riordan et al.
(2006) levels of eGFR (MDRD-4)
Males Females Total p-value
At transplant (ml/min/1.73m2)
Level 1: eGFR ≥90 288 (57.3%) 65 (41.4%) 353 (53.5%) 0.0005a
Level 2: eGFR 60–89 141 (28.0%) 56 (35.7%) 197 (29.8%)
Level 3: eGFR 30–59 67 (13.3%) 29 (18.5%) 96 (14.5%)
Level 4: eGFR 15–29 7 (1.4%) 4 (2.5%) 11 (1.7%)
Level 5: eGFR < 15 0 (0.0%) 3 (1.9%) 3 (0.5%)
Not Recorded 58 20 78
At inclusion visit (ml/min/1.73m2)
Level 1: eGFR ≥90 156 (27.8%) 48 (27.1%) 204 (27.6%) 0.0299a
Level 2: eGFR 60–89 277 (49.4%) 70 (39.6%) 347 (47.0%)
Level 3: eGFR 30–59 117 (20.9%) 57 (32.2%) 174 (23.6%)
Level 4: eGFR 15–29 5 (0.9%) 1 (0.6%) 6 (0.8%)
Level 5: eGFR < 15 6 (1.1%) 1 (0.6%) 7 (1.0%)
At follow-up visit (ml/min/1.73m2)
Level 1: eGFR ≥90 137 (24.4%) 39 (22.0%) 176 (23.9%) 0.25903b
Level 2: eGFR 60–89 278 (49.6%) 78 (44.1%) 356 (48.2%)
Level 3: eGFR 30–59 133 (23.7%) 54 (30.5%) 187 (25.3%)
Level 4: eGFR 15–29 8 (1.4%) 5 (2.8%) 13 (1.8%)
Level 5: eGFR < 15 5 (0.9%) 1 (0.6%) 6 (0.8%)
eGFR estimated Glomerular Filtration Rate, MDRD-4 4 variable Modification of
Diet in Renal Disease study equation
aFisher exact test; bχ2 test
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Kim et al. 2010, chronic kidney disease is observed in 10 to
60% of patients up to 5 years after transplantation. In our
overall population, the proportion of patients with eGFR <
60ml/min/1.73m2 at enrolment (25.3%) fell within the
lower range of proportions reported in the literature. A
possible reason for this may be a potential selection of
patients with good renal prognosis: namely, patients who
received combined multiple-organ transplant or liver re-
transplant were not included in the study, as per exclusion
criteria.
Previous estimates suggest that around 20% of patients
with chronic liver failure develop renal dysfunction even
before LT [3], and this is associated with reduced sur-
vival in patients undergoing both elective and urgent
orthotopic LT [7]. At the time of LT, in our population,
the prevalence of renal damage, as assessed by an eGFR
< 60mL/min/1.73 m2, was 16.67%, which is only slightly
lower than literature data. The increase in the prevalence
of impaired renal filtration observed at the time of initial
study visit (+ 52% vs LT-time) and further during the 1-
year follow-up (+ 67% vs LT-time), confirms that renal
dysfunction had developed in many more patients after
transplantation. Consistently the mean eGFR values pro-
gressively decreased from transplant time to follow-up.
The slope of the eGFR decline, as well as the annual
average change, were much higher during the first post-
transplant year, suggesting a more rapid worsening of
renal function early after LT. Acute renal failure (ARF)
is a serious and frequent clinical problem associated with
liver LT: the incidence of post-LT ARF has been re-
ported to range between 17 and 95% in different studies
and may also be associated with LT surgery [41–44].
The proportion of patients with an impaired GFR was
significantly higher in females at both time of transplant-
ation and study inclusion visit. This suggests that our fe-
male patients arrived at LT in worse renal conditions
compared to males, as confirmed also by patients’ distri-
bution among O’Riordan eGFR levels, that shows a highly
significant sex-difference at the time of LT, once more in-
dicating less renal impairment in men. This observation
seems to confirm the hypothesis by Moylan et al. [31] that
sex disparities still exist in access to LT and women often
arrive at transplantation in worse clinical conditions,
sometimes even too ill to actually receive a transplant. On
the other hand, it has also to be considered that HCC pa-
tients are typically transplanted with MELD exception;
thus, they do not need to accumulate renal dysfunction in
order to access to transplant, as creatinine is part of the
MELD calculation. This too may explain why males had
less renal dysfunction at transplant than females.
Table 4 eGFR (MDRD-4) annual average change (slope) overall and by time from transplant to inclusion visit
eGFR annual average change (slope) from transplant
to inclusion visit (ml/min/1.73m2/year)
p-value
Time elapsed from transplant to inclusion visit N Mean SD 25th percentile Median 75th percentile
[5 months; 1 year) Females 30 −41.6 95.1 −62.0 −24.6 9.2 0.29355*
Males 92 −22.3 50.0 −54.0 −14.8 9.6
Total 122 −27.1 64.2 −56.1 −16.9 9.5
[1 year; 2 years) Females 41 − 5.5 27.3 −23.2 −6.9 3.6 0.1478**
Males 140 −14.8 23.7 −27.6 −11.2 −0.5
Total 181 −12.6 24.8 −25.9 −9.7 −0.3
[2 years; 3 years) Females 33 −6.8 17.7 −12.7 −5.1 −0.2 0.54312*
Males 95 −8.7 14.7 −17.0 −7.6 0.2
Total 128 −8.3 15.5 −16.2 −7.1 −0.2
[3 years; 4 years) Females 28 −4.6 8.1 −10.3 −5.9 −1.0 0.40157*
Males 95 −6.3 9.5 −11.1 −5.3 0.2
Total 123 −5.9 9.2 −10.8 −5.3 −0.2
[4 years; 5.5 years] Females 25 −3.7 11.1 −9.0 −3.7 2.6 0.94751*
Males 81 −3.9 7.8 −10.5 −3.5 1.4
Total 106 −3.8 8.6 −10.3 −3.6 2.6
Total evaluable patients Females 157 −12.2 46.6 −16.7 −5.9 2.6 0.87949*
Males 503 −11.6 26.8 −19.6 −6.7 0.9
Total 660 −11.8 32.6 −19.0 −6.5 1.2
eGFR estimated Glomerular Filtration Rate
SD Standard deviation
*Two-sample T-test p-value
** Wilcoxon-Mann-Whitney test p-value
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When looking at the annual average filtration decline,
interestingly it was lower in women, not reaching statistical
significance in first post-LT year but becoming significant
at the fourth year after transplantation, when females had
even improved and men further slightly worsened. This is
interesting and somewhat surprising, but might be due to
the generally greater muscle mass of males and to the fact
that the use of eGFR has major limitations in cirrhotic pa-
tients. During post-LT course, significantly more females
experienced one or more acute liver rejections from trans-
plant to inclusion visit.
Renal failure remains a major cause of late mortality
after LT [1]. A clear link is recognised between renal
failure and long-term immunosuppressive therapy, and
prolonged use of CNI, in particular, has been associated
with chronic nephrotoxicity after all types of transplant-
ation, as well as during treatment of autoimmune dis-
ease. Almost all transplanted patients in the SURF were
on CNI-based immunosuppressive therapy, mainly with
tacrolimus, either alone or in combination, and this may
have significantly contributed to renal impairment fol-
lowing LT. Considering the more benign trend in eGFR
levels in females compared to males, we wonder whether
women may be less sensitive to the CNI-associated renal
damage. No significant differences in the treatment ap-
proaches have been found, so that we may exclude that
the differences observed in the filtration rate trend may
be due to different therapeutic behaviours. Recently, it
has been suggested that delayed introduction of CNI fol-
lowing LT, and personalization of immunosuppression
by identifying those who may gain maximum benefit
from CNI-avoidance or minimization may, theoretically,
help decrease the negative impact of CNI on renal func-
tion [45–48].
Our study has the limitation of a post-hoc by-sex ana-
lysis, which was not a specified objective of the original
Fig. 1 eGFR, proteinuria and slope categories at inclusion and at follow-up visit by sex
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SURF study. Therefore, the sample size had not been
calculated in order to detect sex differences in the study
endpoints and male and female patients were not prop-
erly balanced. The observational design and the retro-
spective collection of LT data represent other
limitations, in terms of data availability and homogen-
eity. These limitations in the study design make it diffi-
cult to draw definitive conclusions regarding sex and
renal function outcome after LT.
Conclusions
We think that the SURF study sheds some light on the
prevalence of renal impairment before and after LT, and
this post-hoc by-sex analysis suggests potential sex dif-
ferences, encouraging additional clinical research to con-
firm and further explore such differences in the complex
setting of LT. We strongly believe and have also shown
in some recent works [49–52], that men and women dif-
fer with regard to severity and pathogenesis of diseases,
healthcare needs and drug tolerability, and that a uni-
form approach may not always be the best choice for the
patient. Also in the management of liver transplant re-
cipients, sex-based approaches may be needed to
optimize modifiable risk factors and improve post-
transplant renal function.
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